Innovating in cancer and anti-fibrosis treatments
Welcome to TaviraBio, a leading biotech company dedicated to disruptive innovation in the fight against hard-to-treat cancers. Explore our potentially leading first-in-class therapies, our commitment to improving patient outcomes, and our vision for the future of oncology. We are based in the United States and driven by a passion for scientific excellence and impactful solutions.
Our mission
At TaviraBio, our mission is to partner & pioneer innovative therapies from Asia that transform the lives of patients battling hard-to-treat cancers. We strive to deliver breakthrough solutions by leveraging cutting-edge research and a commitment to scientific rigour. Our business is focussed on taking products already in Clinical Trials or ready for them, through Clinical Development & into commercialisation.
Our pipeline
We are building a robust pipeline of novel therapeutics under evaluation targeting key mechanisms in cancer progression. From late pre-clinical to clinical development, we are dedicated to advancing promising candidates with the potential to address unmet medical needs.
Preclinical
Advancing lead compounds through rigorous preclinical studies to assess safety and efficacy.
Clinical
Evaluating the safety and efficacy of our therapeutics in human clinical trials with regulatory interaction to ensure nimble & cost efficient product development, our expertise stretches many decades between the Senior Management of TaviraBio, with multiple Oncology & other products successfully brought to market.
About us
TaviraBio is dedicated to revolutionising cancer treatment through innovative biotechnology. Based in the United States, our team of experts is committed to developing groundbreaking therapies for hard-to-treat cancers. Learn more about our team, our mission, and our approach to tackling the toughest challenges in oncology.
Latest news & insights
Stay up-to-date with the latest news, insights, and breakthroughs from TaviraBio. Explore our research publications, press releases, and commentary on the evolving landscape of cancer treatment.
"TaviraBio is going to be at the forefront of cancer research, with a clear dedication to bringing new treatments to patients in need."
Dr James Phillips (Chairman)
"Their innovative approach and commitment to excellence make TaviraBio a future key player in the fight against cancer."
Dr. Miles Rutherford, Biotech Investor
"TaviraBio's approach holds great promise for developing more effective treatments for aggressive cancers."
Dr. Anya Petrova, Medical Researcher